Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lorand Pop"'
Autor:
B. Gruenberger, Judith Stift, Lorand Pop, Lejla Alidzanovic, Christine Brostjan, Dominic Schauer, Feldman A, Thomas Maier, Thomas Gruenberger, Elisabeth Buchberger, Philipp Zajc, Elleder, Patrick Starlinger, R. Padickakudy, Andreas Spittler
We have previously reported that intermediate monocytes (CD14(++)/CD16(+)) were increased in colorectal cancer (CRC) patients, while the subset of pro-angiogenic TIE2-expressing monocytes (TEMs) was not significantly elevated. This study was designed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce79144b4c40dd46af2a9602dd4c9ba
https://europepmc.org/articles/PMC4938316/
https://europepmc.org/articles/PMC4938316/
Autor:
Judith Stift, Birgit Gruenberger, Patrick Starlinger, Dominic Schauer, Thomas Gruenberger, Christine Brostjan, Ulrike Koeck, Alexandra Feldman, Lejla Alidzanovic, Lorand Pop, Elisabeth Buchberger, Thomas Maier
Publikováno v:
Oncotarget
// Lejla Alidzanovic 1 , Patrick Starlinger 1 , Dominic Schauer 1 , Thomas Maier 1 , Alexandra Feldman 1 , Elisabeth Buchberger 1 , Judith Stift 2 , Ulrike Koeck 3 , Lorand Pop 1 , Birgit Gruenberger 4 , Thomas Gruenberger 1, 5 , Christine Brostjan 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0226a4f7ceccafd52ab2a4428d54b36
https://pubmed.ncbi.nlm.nih.gov/27527865
https://pubmed.ncbi.nlm.nih.gov/27527865
Autor:
Christine Brostjan, Thomas Maier, Philipp Zajc, Lorand Pop, Thomas Gruenberger, Birgit Gruenberger, Patrick Starlinger, Dominic Schauer, Lejla Alidzanovic, Elisabeth Buchberger
Publikováno v:
BMC Immunology
Background Monocytes reportedly contribute to liver regeneration. Three subsets have been identified to date: classical, intermediate, non-classical monocytes. The intermediate population and a subtype expressing TIE2 (TEMs) were suggested to promote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279bbeb503ebfa3b5d7010cae3c4adbf
https://pubmed.ncbi.nlm.nih.gov/25359527
https://pubmed.ncbi.nlm.nih.gov/25359527
Autor:
Christine Brostjan, Lejla Alidzanovic, Thomas Maier, B. Gruenberger, Thomas Gruenberger, Patrick Starlinger, Dominic Schauer, Beata Herberger, Lorand Pop, C. Nemeth
Publikováno v:
Journal of Clinical Oncology. 29:e14005-e14005
e14005 Background: The antibody bevacizumab (Bev) has proven a promising tool for anti-angiogenic cancer therapy by neutralizing vascular endothelial growth factor A (VEGF). Although VEGF is known ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6acebba564e2b79ae07fb69563b1a769
https://doi.org/10.1200/jco.2011.29.15_suppl.e14005
https://doi.org/10.1200/jco.2011.29.15_suppl.e14005